DURECT Corp (DRRX) – Strategy, SWOT and Corporate Finance Report

DURECT Corp (DRRX) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

DURECT Corp (Durect) is a biopharmaceutical company that focuses on the research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. Durect also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.

Scope

• Detailed information on DURECT Corp required for business and competitor intelligence needs

• A study of the major internal and external factors affecting DURECT Corp in the form of a SWOT analysis

• An in-depth view of the business model of DURECT Corp including a breakdown and examination of key business segments

• News about DURECT Corp, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of DURECT Corp and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess DURECT Corp as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on DURECT Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

AstraZeneca Plc

Medtronic Plc

Mallinckrodt Plc

Eli Lilly and Co

Immune Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc

Pacira BioSciences Inc

Knoll Inc

AbbVie Inc

Purdue Pharma LP

Acorda Therapeutics Inc

Avadel Pharmaceuticals Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

DURECT Corp - Key Facts

DURECT Corp - Key Employees

DURECT Corp - Key Employee Biographies

DURECT Corp - Major Products and Services

DURECT Corp - History

DURECT Corp - Company Statement

DURECT Corp - Locations And Subsidiaries

Head Office

Section 2 – Company Analysis

Company Overview

DURECT Corp - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Other

Performance

Geographical Segment: The US

Performance

R&D Overview

DURECT Corp - Corporate Strategy

DURECT Corp - SWOT Analysis

SWOT Analysis - Overview

DURECT Corp - Strengths

DURECT Corp - Weaknesses

DURECT Corp - Opportunities

DURECT Corp - Threats

DURECT Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

DURECT Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023

DURECT Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023

DURECT Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 08, 2023: DURECT reports Q1 2023 financial results and business update

Mar 21, 2023: DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

Mar 07, 2023: DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

Feb 28, 2023: DURECT to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

Nov 02, 2022: DURECT Corp Reports Third Quarter 2022 Financial Results and Update of Programs

Aug 04, 2022: DURECT Reports Second Quarter 2022 Financial Results and Update of Programs

Jul 05, 2022: DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

May 18, 2022: DURECT Corp to Present at the H.C. Wainwright Global Investment Conference

May 04, 2022: DURECT Reports First Quarter 2022 Financial Results and Update of Programs

Mar 23, 2022: DURECT Corp. to Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

DURECT Corp, Key Facts

DURECT Corp, Key Employees

DURECT Corp, Key Employee Biographies

DURECT Corp, Major Products and Services

DURECT Corp, History

DURECT Corp, Key Competitors

DURECT Corp, Ratios based on current share price

DURECT Corp, Annual Ratios

DURECT Corp, Annual Ratios (Cont…1)

DURECT Corp, Annual Ratios (Cont…2)

DURECT Corp, Interim Ratios

DURECT Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023

DURECT Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023

DURECT Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

DURECT Corp, Performance Chart (2018 – 2022)

DURECT Corp, Ratio Charts

DURECT Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023

DURECT Corp, Medical Equipment, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports